Literature DB >> 19191758

Molecular mechanisms in coupling of bone formation to resorption.

T Martin1, Jonathan H Gooi, Natalie A Sims.   

Abstract

Bone remodeling is the process of removal and replacement of bone, taking place at many sites throughout the skeleton and regulated mainly by locally generated factors. Its purposes are to repair damaged bone, remove old bone, and facilitate skeletal responses to changes in loading requirements. Cells of the osteoblast lineage control the formation and activity of osteoclasts, which are responsible for initiation and execution of resorption at remodeling sites. The bone resorbed by osteoclasts is replaced through the differentiation and activity of osteoblasts. The consequent formation must match closely the amount of bone that is resorbed at each site. This coupling of the two processes is essential for bone balance. Both resorption products and osteoclast-derived factors contribute to the coupling of bone formation to resorption in bone remodeling. This review considers the molecular mechanisms and intercellular communication processes involved in remodeling and coupling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191758     DOI: 10.1615/critreveukargeneexpr.v19.i1.40

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  60 in total

1.  Integration of immunity with physical and cognitive function in definitions of successful aging.

Authors:  Patricia Griffin; Joshua J Michel; Kristy Huysman; Alison J Logar; Abbe N Vallejo
Journal:  Aging Dis       Date:  2012-02-27       Impact factor: 6.745

Review 2.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

3.  IGF-1 Signaling is Essential for Differentiation of Mesenchymal Stem Cells for Peak Bone Mass.

Authors:  Janet L Crane; Luo Zhao; Joseph S Frye; Lingling Xian; Tao Qiu; Xu Cao
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

4.  Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro.

Authors:  Susanne Neumann; Elena Eliseeva; Alisa Boutin; Elena Barnaeva; Marc Ferrer; Noel Southall; David Kim; Xin Hu; Sarah J Morgan; Juan J Marugan; Marvin C Gershengorn
Journal:  J Pharmacol Exp Ther       Date:  2017-10-31       Impact factor: 4.030

5.  Serum CTX levels and histomorphometric analysis in Src versus RANKL knockout mice.

Authors:  Sunao Takeshita; Toshio Fumoto; Masako Ito; Kyoji Ikeda
Journal:  J Bone Miner Metab       Date:  2017-06-06       Impact factor: 2.626

Review 6.  Regulation of bone remodeling by vitamin K2.

Authors:  V D Myneni; E Mezey
Journal:  Oral Dis       Date:  2017-04-05       Impact factor: 3.511

7.  Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization.

Authors:  Kuniaki Ota; Patrick Quint; Ming Ruan; Larry Pederson; Jennifer J Westendorf; Sundeep Khosla; Merry Jo Oursler
Journal:  J Cell Biochem       Date:  2013-08       Impact factor: 4.429

Review 8.  Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit.

Authors:  Natalie A Sims; T John Martin
Journal:  Bonekey Rep       Date:  2014-01-08

9.  Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.

Authors:  Nan Su; Qidi Sun; Can Li; Xiumin Lu; Huabing Qi; Siyu Chen; Jing Yang; Xiaolan Du; Ling Zhao; Qifen He; Min Jin; Yue Shen; Di Chen; Lin Chen
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

10.  Overexpression of H1 calponin in osteoblast lineage cells leads to a decrease in bone mass by disrupting osteoblast function and promoting osteoclast formation.

Authors:  Nan Su; Maomao Chen; Siyu Chen; Can Li; Yangli Xie; Ying Zhu; Yaozong Zhang; Ling Zhao; Qifen He; Xiaolan Du; Di Chen; Lin Chen
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.